drugset
drugset / Trial / NCT05169697

A Study to Assess YH002 in Combination with YH001 in Subjects with Advanced Solid Tumors

NCT05169697 ↗

Phase 1 Completed 6 enrolled Eucure (Beijing) Biopharma Co., Ltd
NaSingle-groupOpen-labelTreatment

Summary

A multicenter, open-label, phase I dose escalation study to evaluate the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of YH002 in combination with YH001 in subjects with advanced solid tumors

Timeline

Start
2022-02-21
Primary completion
2023-07-04
Completion
2023-07-04

Drugs

EvaluationDrugModalityDoseRoute
Subject YH001 Unknown — —
Subject YH002 Unknown — —

Indications

neoplasm